Terms: = Lymphoma AND BCL10, CIPER, 8915, ENSG00000142867, c-E10, CARMEN, mE10, CLAP AND Treatment
65 results:
1. Dimethyl Fumarate Suppresses the Proliferation of HTLV-1-infected T Cells by Inhibiting CBM Complex-triggered NF-B Signaling.
Sato T; Maeta T; Ito S
Anticancer Res; 2023 May; 43(5):1901-1908. PubMed ID: 37097671
[TBL] [Abstract] [Full Text] [Related]
2. Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma.
Ferreri AJM; Angelillo P; Erbella F; Cattaneo C; Verga L; Lleshi A; Allione B; Ponzoni M; Facchetti F; Pagani C; Foppoli M; Pecciarini L; Sassone M; Steffanoni S; Flospergher E; Rossi G; Spina M; Re A
Blood Adv; 2022 Nov; 6(22):5811-5820. PubMed ID: 35580327
[TBL] [Abstract] [Full Text] [Related]
3. Clinical and Immunological Features of Human bcl10 Deficiency.
Garcia-Solis B; Van Den Rym A; Pérez-Caraballo JJ; Al-Ayoubi A; Alazami AM; Lorenzo L; Cubillos-Zapata C; López-Collazo E; Pérez-Martínez A; Allende LM; Markle J; Fernández-Arquero M; Sánchez-Ramón S; Recio MJ; Casanova JL; Mohammed R; Martinez-Barricarte R; Pérez de Diego R
Front Immunol; 2021; 12():786572. PubMed ID: 34868072
[TBL] [Abstract] [Full Text] [Related]
4. Targeting MALT1 for the treatment of diffuse large B-cell lymphoma.
Seshadri MR; Melnick AM
Leuk Lymphoma; 2022 Apr; 63(4):789-798. PubMed ID: 34783281
[TBL] [Abstract] [Full Text] [Related]
5. MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer.
Lee JL; Ekambaram P; Carleton NM; Hu D; Klei LR; Cai Z; Myers MI; Hubel NE; Covic L; Agnihotri S; Krappmann D; Bornancin F; Lee AV; Oesterreich S; McAllister-Lucas LM; Lucas PC
Mol Cancer Res; 2022 Mar; 20(3):373-386. PubMed ID: 34753803
[TBL] [Abstract] [Full Text] [Related]
6. Intrinsic Abnormalities of Keratinocytes Initiate Skin Inflammation through the IL-23/T17 Axis in a MALT1-Dependent Manner.
Zhang S; Wang M; Wang C; Wang G; Sun K; Xiong S; Cheng L; Yang D; Lin X; Zhao X
J Immunol; 2021 Feb; 206(4):839-848. PubMed ID: 33419765
[TBL] [Abstract] [Full Text] [Related]
7. Targeting bcl10 by small peptides for the treatment of B cell lymphoma.
Bao W; Sun C; Sun X; He M; Yu H; Yan W; Wen F; Zhang L; Yang C
Theranostics; 2020; 10(25):11622-11636. PubMed ID: 33052237
[No Abstract] [Full Text] [Related]
8. Critical protein-protein interactions within the CARMA1-bcl10-MALT1 complex: Take-home points for the cell biologist.
Cheng J; Maurer LM; Kang H; Lucas PC; McAllister-Lucas LM
Cell Immunol; 2020 Sep; 355():104158. PubMed ID: 32721634
[TBL] [Abstract] [Full Text] [Related]
9. MALT1 is a critical mediator of PAR1-driven NF-κB activation and metastasis in multiple tumor types.
McAuley JR; Bailey KM; Ekambaram P; Klei LR; Kang H; Hu D; Freeman TJ; Concel VJ; Hubel NE; Lee JL; Klei HB; Cheng J; Sekar P; Bridwell RE; Covic L; Lucas PC; McAllister-Lucas LM
Oncogene; 2019 Dec; 38(49):7384-7398. PubMed ID: 31420608
[TBL] [Abstract] [Full Text] [Related]
10. Germline CBM-opathies: From immunodeficiency to atopy.
Lu HY; Biggs CM; Blanchard-Rohner G; Fung SY; Sharma M; Turvey SE
J Allergy Clin Immunol; 2019 May; 143(5):1661-1673. PubMed ID: 31060714
[TBL] [Abstract] [Full Text] [Related]
11. Cardiovascular mortality among patients with non-Hodgkin lymphoma: Differences according to lymphoma subtype.
Abuamsha H; Kadri AN; Hernandez AV
Hematol Oncol; 2019 Aug; 37(3):261-269. PubMed ID: 30916804
[TBL] [Abstract] [Full Text] [Related]
12. By regulating miR-182-5p/bcl10/CYCS, sufentanil reduces the apoptosis of umbilical cord mesenchymal stem cells caused by ropivacaine.
Li L; Sun Y; Zhang N; Qiu X; Wang L; Luo Q
Biosci Trends; 2019 Mar; 13(1):49-57. PubMed ID: 30773504
[TBL] [Abstract] [Full Text] [Related]
13. The CARMA3-bcl10-MALT1 Signalosome Drives NFκB Activation and Promotes Aggressiveness in Angiotensin II Receptor-Positive Breast Cancer.
Ekambaram P; Lee JL; Hubel NE; Hu D; Yerneni S; Campbell PG; Pollock N; Klei LR; Concel VJ; Delekta PC; Chinnaiyan AM; Tomlins SA; Rhodes DR; Priedigkeit N; Lee AV; Oesterreich S; McAllister-Lucas LM; Lucas PC
Cancer Res; 2018 Mar; 78(5):1225-1240. PubMed ID: 29259013
[TBL] [Abstract] [Full Text] [Related]
14. First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma.
Kuo SH; Yeh KH; Wu MS; Lin CW; Wei MF; Liou JM; Wang HP; Chen LT; Cheng AL
Sci Rep; 2017 Oct; 7(1):14333. PubMed ID: 29084984
[TBL] [Abstract] [Full Text] [Related]
15. CARMA2sh and ULK2 control pathogen-associated molecular patterns recognition in human keratinocytes: psoriasis-linked CARMA2sh mutants escape ULK2 censorship.
Scudiero I; Mazzone P; D'Andrea LE; Ferravante A; Zotti T; Telesio G; De Rubis G; Reale C; Pizzulo M; Muralitharan S; Vito P; Stilo R
Cell Death Dis; 2017 Feb; 8(2):e2627. PubMed ID: 28230860
[TBL] [Abstract] [Full Text] [Related]
16. MALT lymphoma: A paradigm of NF-κB dysregulation.
Du MQ
Semin Cancer Biol; 2016 Aug; 39():49-60. PubMed ID: 27452667
[TBL] [Abstract] [Full Text] [Related]
17. Lymphocyte signaling and activation by the CARMA1-bcl10-MALT1 signalosome.
Meininger I; Krappmann D
Biol Chem; 2016 Dec; 397(12):1315-1333. PubMed ID: 27420898
[TBL] [Abstract] [Full Text] [Related]
18. Successful clinical treatment and functional immunological normalization of human MALT1 deficiency following hematopoietic stem cell transplantation.
Rozmus J; McDonald R; Fung SY; Del Bel KL; Roden J; Senger C; Schultz KR; McKinnon ML; Davis J; Turvey SE
Clin Immunol; 2016 Jul; 168():1-5. PubMed ID: 27109639
[TBL] [Abstract] [Full Text] [Related]
19. Targeting Non-proteolytic Protein Ubiquitination for the treatment of Diffuse Large B Cell lymphoma.
Yang Y; Kelly P; Shaffer AL; Schmitz R; Yoo HM; Liu X; Huang DW; Webster D; Young RM; Nakagawa M; Ceribelli M; Wright GW; Yang Y; Zhao H; Yu X; Xu W; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza L; Staudt LM
Cancer Cell; 2016 Apr; 29(4):494-507. PubMed ID: 27070702
[TBL] [Abstract] [Full Text] [Related]
20. MALT1 Protease Activity Controls the Expression of Inflammatory Genes in Keratinocytes upon Zymosan Stimulation.
Schmitt A; Grondona P; Maier T; Brändle M; Schönfeld C; Jäger G; Kosnopfel C; Eberle FC; Schittek B; Schulze-Osthoff K; Yazdi AS; Hailfinger S
J Invest Dermatol; 2016 Apr; 136(4):788-797. PubMed ID: 26767426
[TBL] [Abstract] [Full Text] [Related]
[Next]
